On Saturday October 14th, at the Â鶹´«Ã½ presented a first disclosure of NP1867; a potent, selective, covalent small molecule inhibitor of DNA Mismatch Repair (MMR) protein PMS2. We showed, for the first time, that NP1867 functionally inhibits MMR in cells and elicits COSMIC mutational signatures consistent with MMR-deficient patient samples.
To download the poster please submit the form below.
Â鶹´«Ã½'s CEO - Michael Shih - recently presented the Â鶹´«Ã½ story at the Morgan Stanley Global Healthcare Conference on Monday September 8th …
Â鶹´«Ã½ appoints Michael Shih as Chief Executive Officer Highly experienced corporate development leader with a track record of international pharma …
Â鶹´«Ã½ closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb Additional funding will be used to explore …